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Background: Serum cystatin C (ScysC) may help predicting cardiovascular outcome not only through its ability to
detect renal dysfunction but also through its potential connection to others factors that are directly related to
cardiovascular diseases. We explored the potential association of ScysC with arterial stiffness - a major contributor
to cardiovascular disease - in renal transplant recipients (RTR).
Methods: Traditional and non-traditional cardio-vascular risk factors were collected from 215 stable RTR whom
arterial stiffness was evaluated by the measure of the augmentation index of central pressure (AIx) determined
by the arteriograph device. Serum creatinine and ScysC were measured the same day using standardized
methods. Association between ScysC and AIx was examined in univariate and multivariate linear regression analysis.
Results: In univariate analysis, ScysC was strongly associated with AIx. This relationship was not confounded by age,
gender, length of time spent on dialysis and transplantation vintage. Adjustment on the level of GFR estimated by the
MDRD Study equation attenuated but did not abolish the association between ScysC and AIx.
Conclusions: In conclusion, ScysC is an independent predictor of AIx in RTR. Our data suggest that arterial stiffness
may partially mediate the association between ScysC and cardiovascular risk in renal transplantation.
Keywords: Cystatin C, Arterial stiffness, Cardiovascular risk, Renal transplantationBackground
Cardiovascular diseases are particularly prevalent in
renal transplant recipients (RTR) and represent a leading
cause of patients’ death and graft loss [1,2]. Besides trad-
itional risk factors such as dyslipidemia, diabetes or
hypertension, others factors more specific to RTR are
thought to be in play and to explain the excess of risk seen
in transplantation. Those non-traditional factors (e.g. cal-
cineurin inhibitor use, length of time spent on dialysis) are
not taken into account by the commonly used risk-
prediction equations, which tend to systematically underesti-
mate the risk of RTR [3,4]. More importantly, identification* Correspondence: mirianadinic@free.fr
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significantly improve risk prediction in RTR is still limited.
The interest of Serum cystatin C (ScysC) as an alterna-
tive –and somehow superior - GFR marker to serum
creatinine has recently been highlighted in the general
population and in patients with native chronic kidney disease
(CKD) [5]. Beyond its role in evaluating renal function,
ScysC is more and more regarded as a potential cardiovascu-
lar risk factor [6,7]. A close relationship between ScysC and
cardiovascular morbi-mortality has been reported in the gen-
eral population as well as in patients with various degrees of
CKD [8]. In renal transplantation, we have confirmed the
validity of ScysC as an endogenous marker of renal graft
function [9] and have recently reported a stronger associ-
ation (as compared to serum creatinine) between ScysC
concentration and RTR mortality [10].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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cular outcome is thought to be explained not only by
the ability of ScysC to detect renal function impairment
(which is by itself a strong cardiovascular risk factor) but
also by its possible connection to others factors that are
directly related to cardiovascular diseases [11]. In this re-
gard, ScysC has recently been suggested, in the general
population [12-15], to be independently associated with
excessive arterial stiffness, a condition that has attracted
considerable interest in cardiovascular epidemiology [15].
Arterial stiffness is currently considered by many as a
major contributor - independent to classical cardio-vascular
risk factors- for cardiovascular mortality, coronary events
and strokes in the general population [16,17] and in patients
with essential hypertension [18,19], type 2 diabetes [20], or
end-stage renal disease [21,22]. From a mechanistic stand-
point, excessive arterial stiffness is responsible for a prema-
ture return of the reflected pulse wave in the late phase of
systole, which causes an increase in central pulse pressure
and thus an excess of workload and oxygen demand for the
left ventricle. The augmentation of central pulse pressure
may also directly influence arterial remodeling and acceler-
ates the development of stenosis and plaques in cerebral ar-
teries. In renal transplantation, arterial stiffness has been
associated with the occurrence of cardiovascular events and
an excess of mortality suggesting that it also acts as a signifi-
cant contributor of cardio-vascular diseases in this particular
setting [23].
Herein, we aimed to better understand the cardiovas-
cular dimension of ScysC in renal transplantation. We
sought to verify whether the association between ScysC
and arterial stiffness seen in the general population could
extend to RTR and explored the confounding role of




From December 2012 to August 2013, all prevalent renal
transplant recipients with a functioning graft and attend-
ing the outpatient clinics at the Saint Etienne University
Hospital for their annual check-up were eligible for the
study. Inclusion criteria were age ≥18 years, time after
transplantation ≥6 months and a stable clinical condi-
tion. This study was approved by the institutional review
board (Comité de Protection des Patients, reference num-
ber 2012–35) and written informed consent obtained
from each participant. The investigation conformed to the
principles outlined in the Declaration of Helsinki. This
study is non-controlled, cross-sectional evaluation of
central hemodynamics parameters in renal transplant
patients.
As part of the standard check-up, the following clinical
parameters were collected: weight, height, abdominalperimeter, brachial artery blood pressure in triplicate
using a validated oscillometric technique (HEM_7223
Omron Healthcare, Kyoto, Japan). We systematically
interrogated patients and inventoried patients’ file for
personal and family history of cardiovascular disease
(defined as a first-degree male relative having suffered
a cardiovascular disease before the age of 55, or a first-
degree female relative having suffered one before the age
of 65), diabetic and smoking status, anti-hypertensive
drugs (number and type), immunosuppressive drugs
(type and posology), history of acute or chronic graft
rejection, age at the time of renal transplant, total time
on renal replacement therapy and type of renal replace-
ment therapy, etiology of native nephropathy, characteris-
tics of the donor (age, height), cold ischemia time. The
Kauppila abdominal aortic calcification score [24] was
assessed from a lateral lumbar X-ray realized the day of
the annual visit.
Laboratory measurements
All biological parameters were measured the same day and
at a single laboratory. Serum creatinine and ScysC were both
measured using standardized methods, IDMS-traceable en-
zymatic method (Crea Vitros) and IFCC-traceable N Latex
cystatin kit (Siemens), respectively. The following parame-
ters were additionally measured: calcemia, phosphoremia,
magnesemia, total cholesterol blood level, high and low-
density lipoprotein cholesterol, hematocrit, hemoglobin,
HbA1C, 25 hydroxy-vitamin D, parathyroid hormone,
proteinuria, micro-albuminuria, C-reactive protein, immuno-
suppressive drug trough levels (tacrolimus, cyclosporine,
everolimus and sirolimus), peripheral CD4+ cells count,
cytomegalovirus PCR, and homocysteinemia.
Assessment of arterial stiffness
Central Hemodynamic Parameters (central blood pres-
sure, central pressure augmentation index and pulse wave
velocity) were recorded in the non-fistula arm using a
validated oscillometric device (Arteriograph®, Medexpert).
Only the central pressure augmentation index (AIx) was
considered for the analysis of arterial stiffness in this study
(Figure 1).
Statistical analysis
Descriptive statistics were used to evaluate recipient-,
donor- and transplantation-related characteristics. Quanti-
tative data are expressed as means ± SD and as percentage
for categorical variables.
Linear regression analysis was performed to assess the
association between different co-variables and AIx. A first
selection of potentially interesting variables was made
based on their theoretical and/or described impact on
arterial stiffness. The relationship between each of these
variables and AIx was first tested in univariate models.
Figure 1 Pulse wave analysis. The arterial pressure waveform is
the sum of the forward wave following ventricular contraction and a
backward wave reflected from the periphery. In vessels with normal
elasticity, the wave velocity is sufficiently low to allow reflection of
the backward wave at the aortic root during diastole. In the case of
increased stiffness, velocity increases causing a premature reflection
of the backward wave during systole. This phenomenon is
quantified through the augmentation index (AIx)—defined as the
difference between the second and first systolic peaks (P1-P2,
absolute augmentation pressure) expressed as a percentage of the
pulse pressure (P1-P3).
Table 1 Demography
Parameters All patients (n = 215)
Age (years) 55.9 ± 13
Time since transplantation (years) 9.2 (0.5-34)
Time spent on dialysis (years) 3 (0–26.3)
Gender (male) (%) 67.4
Type of dialysis (HD) (%) 81.4
Height (m) 1.68 ± 0.07
BMI (kg/m2) 25 ± 5.8
Abdominal perimeter (cm) 93.1 ± 13.1
Current smoker (%) 14.9
Diabetes (%) 18.6
Personal cardiovascular history (%) 16,3
Coronaropathy (%) 10,2
Stroke (%) 6
Peripheral arteriopathy (%) 3,3
Serum Creatinine (μmol/l) 140.7 ± 55.3
eGFR (ml/min/1.73 m2) 52 ± 22
Serum Cystatin C (mg/l) 1.68 ± 0.65
Serum Homocystein (μmol/l) 18.6 ± 8.2
CRP (mg/l) 9,2 ± 20.6
Glycemia (mmol/l) 6.2 ± 8.3
Cholesterol total (mmol/l) 4.9 ± 1.1
HDL-cholesterol (mmol/l) 1.35 ± 0.42
Calcemia (mmol/l) 2.69 ± 0.68
Phosphoremia (mmol/l) 1.16 ± 0.16
Magnesemia (mmol/l) 0.70 ± 0.08
Parathormone (ng/l) 129.68 ± 60.84
HR (bpm) 67 ± 9.7
Brachial SBP (mm Hg) 138 ± 17.1
Brachial DBP (mm Hg) 77.7 ± 10.2
Aortic calcification (mean Kauppila score) 2.8 (0–24)
Treatment
ACE inhibitors/ARB (%) 63,3
Beta-blockers (%) 38,1





Cyclosporine level (μg/l) 81,7 ± 51,3
Tacrolimus (%) 84,7
Tacrolimus level (ng/ml) 6,4 ± 2,1
mTOR inhibitor 8,4
mTOR level (ng/ml) 4,4 ± 2
Corticosteroids (%) 15,3
HR, Heart Rate; SBP, Systolic Blood pressure; DBP, Diastolic Blood Pressure; ACE,
Angiotensin Converting Enzyme; ARB, Angiotensin Receptor Blockers.
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with their 95% confidence interval as well as their p value
from t test. Intercepts were not displayed. Multivariate
models were then built in a forward manner to optimize
the overall goodness-of-fit of the model, by maximizing R2
adjusted on the number of covariates. Variables that were
the most strongly associated to AIx (p < 0.05 in univariate
models) were eligible to be integrated to the multivariate
models and only those which resulted in adjusted R2 im-
provement were finally retained. A p-value associated to a
given coefficient below 0.05 and a 95% confidence interval
outside of the 0 value were considered to be significant.
Each model was checked to provide normally distributed
residuals (quantile-quantile plots, not displayed).
Model comparison was performed with ANalysis Of
VAriance (ANOVA). The p-value associated to F-statistics
below 0.05 was considered as a significant improvement
of the accuracy of the second tested model over the first
one.
A bivariate cubic spline regression model was built to
predict AIx from both creatinine and Cystatin C. Residuals
from this model were normally distributed. This model
was illustrated in a 3-dimensional chart.
Data were analysed using R software (Version 2.15.2).
R core team (2012). R : A language and environment for




Two hundred and fifteen RTR were retained for the ana-
lysis. Characteristics of the population at the time of
Table 2 Central hemodynamic parameters
Mean ± SD Median Range
Aortic SBP (mm Hg) 131.1 ± 23.1 126.3 88.7 - 224.7
Aortic pulse pressure (mm Hg) 47.8 ± 16 44 25.2 - 113.7
Aortic AIx (75) 25.7 ± 15.3 24.9 −3.2 - 59.1
Aortic PWV (m/s) 9.3 ± 1.8 9.3 4.9 - 15.2
SBP, Systolic Blood Pressure; PWV, Pulse Wave Velocity.
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almost exclusively transplanted from a deceased donor
(4.2% of living donor), were treated for hypertension for
more than 85% of them and were receiving a calcineurin
inhibitor-based regimen for more than 95% of them. Mean
serum creatinine and serum cystatin C were 140.7 μmol/l
and 1.68 mg/l, respectively. Mean GFR estimated by the
MDRD Study equation was 52.2 ml/min/1.73 m2. Descrip-
tive statistics of the central hemodynamic parameters are
shown in Table 2.Association between ScysC and AIx
ScysC was positively associated with AIx following a
monotonic increasing curve. In comparison, the relation
between serum creatinine and AIx followed a J-shaped
curve (Figure 2). In univariate analysis, ScysC was signifi-
cantly associated with AIx (P <0.001). All significantFigure 2 Three dimensional representation of a bivariate spline regrecovariates are displayed in Table 3. In contrast, the follow-
ing variables turned out to be not significantly associated
with AIx: albuminuria, diabetes and smoking status, LDL
and HDL cholesterol, C reactive protein, vitamin D, familial
history of cardiovascular diseases, renin-angiotensin system
blockers, calcineurin use and systemic exposure, use of
steroids, history of chronic rejection, CD4+ lymphopenia,
CMV replication.Multivariate analysis
Only variables significantly associated with AIx in the
univariate analysis and that resulted in an increase of the
model adjusted R2 were retained in the final multivariate
regression analysis. Different models with increasing per-
formance were successively built. Model 1 included age,
time on dialysis, transplantation time and SBP. Integra-
tion of ScysC into this model substantially improved its
overall performance (Model 2). After adjustment for eGFR
(Model 3) and for height and gender (Model 4), the as-
sociation between AIx and ScysC was attenuated but
remained statistically significant (Table 4).
In order to better apprehend the added value of ScysC
beyond its capacity to reflect GFR, we compared the per-
formance of models based on eGFR and integrating or not
ScysC. Interestingly, adding ScysC in both univariate and
multivariate eGFR-based models significantly improved
the overall performance of the model (Table 5).ssion model to predict AIx from both Creatinine and Cystatin C.




Age (per year) 0.40 0.25 to 0.54 <0.001
Gender (Female vs. Male) 7.12 2.87 to 11.4 0.001
Height (per meter) −35.4 −58.2 to −12.6 0.003
Transplantation time (per year) −0.348 −0.65 to
−0.050
0.022
Time on dialysis (per year) 0.730 0.16 to 1.29 0.012
Dialysis method (Peritoneal dialysis
and none vs. Hemodialysis)
5.76 0.54 to 11.0 0.03
Personal Cardiovascular history
(yes vs. no)
6.98 1.49 to 12.5 0.013
SBP (per mmHg) 0.34 0.24 to 0.43 <0.001
DBP (per mmHg) 0.33 0.18 to 0.48 <0.001
Diuretic use (yes vs. no) 6.86 2.49 to 10.7 0.002
eGFR (per mL/min/1.73 m2) −0.187 −0.28 to −0.10 <0.001
Cystatin C (per mg/L) 7.69 4.43 to 10.9 <0.001
Mg (per mmol/L) 26.2 6.6 to 45.7 0.008
Homocysteinemia (per mg/L) 0.40 0.15 to 0.65 0.002
PTH (per ng/L) 0.030 0.006 to 0.054 0.014
Ca (per mmol/L) −19.82 −32.8 to −6.77 0.003
P (per mmol/L) 16.2 7.2 to 25.1 <0.001
Kauppila score (per unit) 0.94 0.49 to 1.39 <0.001
Estimates represent the variation of AIx for each unit of the covariate. P values
below 0.05 mean that the covariate is significantly associated to AIx.
SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; eGFR, Estimated
Glomerular Filtration Rate (MDRD Study Equation); Mg, Magnesiemia; PTH,
Parathyroid Hormone; Ca, Calcemia; P, Phosphatemia.




Model 1 <0.001 0.302
Intercept −27.1 −42.1 to −12.1 <0.001
Age 0.319 0.163 to 0.475 <0.001
Time on dialysis 0.781 0.289 to 1.273 0.002
Transplantation time −0.403 −0.682 to −0.124 0.004
SBP 0.275 0.174 to 0.375 <0.001
Model 2 <0.001 0.345
Intercept −28.8 −45.0 to −12.6 <0.001
Age 0.251 0.07 to 0.428 0.006
Time on dialysis 0.745 0.231 to 1.258 0.005
Transplantation time −0.456 −0.764 to −0.148 0.004
SBP 0.245 0.136 to 0.355 <0.001
Cystatin C 5.81 2.60 to 9.03 <0.001
Model 3 <0.001 0.346
Intercept −24.5 −46.7 to −2.34 0.03
Age 0.246 0.067 to 0.425 0.007
Time on dialysis 0.741 0.223 to 1.26 0.005
Transplantation time −0.453 −0.764 to −0.141 0.005
SBP 0.245 0.133 to 0.357 <0.001
Cystatin C 4.82 0.234 to 9.40 0.039
eGFR −0.045 −0.185 to 0.095 0.53
Model 4 <0.001 0.388
Intercept 3.23 −60.6 to 67.0 0.92
Age 0.241 0.066 to 0.416 0.005
Time on dialysis 0.636 0.123 to 1.15 0.01
Transplantation time −0.436 −0.741 to −0.130 0.005
SBP 0.266 0.155 to 0.376 <0.001
Cystatin C 5.70 1.19 to 10.20 0.01
eGFR −0.012 −0.151 to 0.127 0.87
Height −22.3 −53.9 to 9.17 0.16
Gender 3.27 −2.89 to 9.43 0.3
P values below 0.05 mean that the covariate is significantly and independently
associated to AIx.
SBP: Systolic Blood Pressure. eGFR: Estimated-GFR estimation (MDRD Study
equation). Variables displayed with a bold font are added to the
previous model.
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Cardiovascular disease is an important cause of morbid-
ity and mortality in patients with chronic kidney disease.
This is thought to be explained by a phenomenon of
premature aging of the vascular system which results in
an increase of arterial stiffness in this population. The
pathophysiology of this vascular disorder is not well under-
stood. Importantly, while arterial stiffness has been well
characterized in pre-dialysis and dialysis patients, few data
are available for transplant patients [25].
The main finding of our study is that ScysC is signifi-
cantly associated to AIx in RTR and so, independently of
other covariates known to be associated with AIx and/or
to cardiovascular morbi-mortality. In this respect, we
sought to incorporate in our analysis not only the trad-
itional confounders (such as age, systolic blood pressure,
diabetes, dyslipidemia) but also more transplant-specific
factors that have been previously connected to AIx (donor
age [26], magnesemia [27] or cardiovascular complications
(aortic calcification [24], CMV replication [28], CD4+
lymphopenia [29]). In addition, the association between
ScysC and AIx remained independent after adjustment to
eGFR suggesting that an increase in ScysC concentrationmight not only reflect impairment in renal function but
also to a certain extent excessive arterial stiffness. The par-
tial independency of ScysC from renal function would
however need to be confirmed by analyzing “true” GFR
(i.e. a GFR measured using a reference method) rather
than an estimate of GFR. Obviously, the alternative ex-
planation is that ScysC, simply by reflecting more ac-
curately renal function than serum creatinine, is more
strongly associated to AIx. This latter hypothesis is in
line with previous data showing that (i) renal function
Table 5 Comparison of eGFR based models before and after adding serum Cystatin C as a covariable (ANOVA)
R2 without Cystatin C R2 with Cystatin C F statistics p value
eGFR alone vs. (eGFR + Cystatine C) 0.090 0.114 4.14 0.044
Model 4 vs. (Model 4 – Cystatin C) 0.362 0.388 6.25 0.014
Addition of Cystatin C significantly improved both univariate and multivariate mGFR based models.
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is a better GFR maker than serum creatinine in renal
transplantation [9]. Regardless of the underlying mech-
anism and given that the current guidelines recom-
mend to evaluating the level of renal function and its
related risk with creatinine-based estimates [31], we be-
lieve that the eGFR-independent connection of ScysC to
AIx is, from a practical point of view, relevant.
To our knowledge, our study is the first to report an
association between ScysC and AIx in renal transplant-
ation. Previous studies have however reported similar as-
sociation between ScysC and arterial stiffness in older
adults [13] and in the general population with no appar-
ent CKD [12,14]. At odds with those studies, ours did
not rely on the direct measure of pulse wave velocity
(PWV) by applanation tonometry (the real gold standard
of arterial stiffness evaluation) but on the measure of
central pressure augmentation (i.e. a proxy of PWV)
using a more convenient and less operator-dependent
oscillometric method. Importantly, this method has been
validated against the gold standard approach and has
already been utilized in a study reporting an association
between ScysC and AIx in hypertensive patients [15].
Irrespective of the abiblty of ScysC to account for
renal dysfunction, the biological properties of ScysC can
provide some physiopathological basis to its association
with AIx. Cystatin C is a cysteine protease inhibitor that
controls the activity of cathepsins. Through their elasto-
lytic and collagenolytic activities, cathepsins may contrib-
ute to atherosclerogenesis. Overexpression and overactivity
of cathepsins are found in human atherosclerotic lesions
[32]. In response to this overexpression, cystatin C produc-
tion might be stimulated to regulate cathepsins activity. In
this purely speculative scenario, elevated ScysC concentra-
tion would only be an indirect marker of cathepsin-
induced arterial stiffness.
Several strengths of our study can be pointed. First,
this is a single-center, prospectively planned study with
careful selection of all clinical variables and centralized
measurement of all biological variables. Measurement of
serum creatinine and ScysC were both standardized.
Second, we selected co-variates of interest not only
based on the literature available in the general population
but also with a special focus on risk factors specifically
identified in previous renal transplant cohorts. Third, we
sought to analyze certain covariates in the most inform-
ative way possible: the “immunosuppressive drugs” vari-
able was assessed according to the type of drug and to thesystemic exposure to the drug; the “anti-hypertensive
treatment” covariate, according to the type and to the
number of drugs.
Several limitations of our study must similarly be con-
sidered. First of all, the cross-sectional design of our
study precludes us from making any causal inference in
the association between covariates and AIx. Even the
direction of the association might be difficult to ascer-
tain in this context. Since our patients are exclusively
Caucasians, transplanted mainly form deceased donors,
our results may not be generalizable to other popula-
tions. Additionally, we cannot rule out the possibility of
unmeasured confounding from variables that were not
evaluated in our study (e.g. we did not include in our
analysis the presence of a functioning fistula, a variable
that has been previously associated with arterial stiffness
in RTR [33]). Finally, since GFR was not directly mea-
sured by a reference method, we cannot clarify whether
the association between ScysC and AIx is or is not solely
explained by the association between ScysC and renal
function.
Conclusions
In conclusion, elevated ScysC concentration is independ-
ently associated with AIx in stable RTR. This relation-
ship is not confounded by age, gender, length of time
spent on dialysis and transplantation vintage neither by
the level of GFR estimated by the MDRD Study equa-
tion. Our data suggest that arterial stiffness may partially
mediate the association between ScysC and cardiovascu-
lar risk in renal transplantation. Whether the association
between ScysC and arterial stiffness reflects the direct
implication of ScysC in atherosclerogenesis or solely its
ability to approximate GFR will need further research.
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